Formulary And Therapeutic Alternatives - NAPLEX

BX rating. Products with this rating lack sufficient data to prove bioequivalence, making them unsuitable for substitution with the reference drug.

Insulin detemir (or institution-preferred basal insulin). Hospitals prefer long-acting analogs like detemir for basal coverage, ensuring similar glycemic control and standardization in inpatient settings.

AA rating. This rating applies to drugs like solutions where bioequivalence studies are unnecessary, confirming they perform similarly to the reference.

Branded generic. These are off-patent drugs sold by manufacturers under proprietary names, offering identical active ingredients but branded marketing.

Biosimilar. Approval requires demonstration of high similarity in structure, function, and clinical outcomes to the reference biologic product.

Interchangeable biosimilar. This designation allows automatic pharmacy-level substitution without prescriber intervention, similar to generic drugs, if state laws permit.

Omeprazole. As a first-generation PPI, it provides equivalent acid suppression for GERD or ulcers, often at lower cost without significant interaction differences.

Atorvastatin. It offers comparable LDL reduction at high doses, making it an effective substitute for high-intensity statin therapy in lipid management.

Use a non-beta-lactam or aztreonam when appropriate. True penicillin allergies risk cross-reactivity with beta-lactams, so alternatives like aztreonam or non-beta-lactam classes minimize anaphylaxis risk.

IV-to-PO conversion (use equivalent oral regimen). Switching to oral forms reduces costs and infection risks when drugs have high oral absorption, maintaining equivalent therapeutic effects.

Therapeutic interchange per protocol to formulary agent. Protocols allow automatic replacement with a therapeutically equivalent formulary drug to maintain efficacy while controlling institutional costs.

Avoid switching when possible; monitor levels/response closely. NTI drugs have small margins between therapeutic and toxic doses, so minimizing switches and close monitoring prevent variability in response.

Clopidogrel. As a P2Y12 inhibitor, it provides similar antiplatelet effects for conditions like ACS, serving as a cost-effective alternative without contraindications.

Dispense AB-rated generic equivalent for brand. Pharmacies perform this to reduce costs by replacing a brand-name drug with its bioequivalent generic version rated as interchangeable.

Authorized substitution to a different drug in same class. Institutions implement this to standardize therapy by switching to an equivalent formulary drug within the same therapeutic class for efficiency.

Prior authorization. This strategy ensures appropriate utilization of expensive medications through prescriber documentation and payer approval prior to dispensing.

Open formulary. This flexible design allows coverage for most drugs, including non-preferred ones, often at higher patient cost or with approval processes.

Closed formulary. It strictly limits coverage to approved drugs only, encouraging use of cost-effective options and excluding non-listed medications entirely.

Tiered formulary. Tiers incentivize selection of preferred drugs through lower copays for generics or formulary brands and higher costs for nonpreferred options.

Refill limit (or days-supply limit). It controls chronic use and costs by restricting the total refills or supply duration available over a specified timeframe.

Quantity limit. This restriction promotes safe usage and prevents stockpiling or diversion by capping the maximum amount allowable per prescription period.

Prior authorization. It requires prescriber justification based on specific medical necessity criteria to ensure appropriate and cost-effective use of the medication.

Step therapy (fail-first requirement). This approach ensures cost-effectiveness by mandating failure on a less expensive preferred drug before approving a more costly nonpreferred option.

Generic substitution to AB-rated equivalent. Using an AB-rated generic lowers expenses without compromising efficacy, as it is bioequivalent to the nonpreferred brand-name drug.